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The increasing prevalence of obesity is a fundamental contributor to the growing prevalence of the metabolic syndrome. Rexi-
noids, a class of compounds that selectively bind and activate RXR, are being studied as a potential option for the treatment of
metabolic syndrome. These compounds have glucose-lowering, insulin-sensitizing, and antiobesity eﬀects in animal models of
insulin resistance and type 2 diabetes. However, undesirable side eﬀects such as hypertriglyceridemia and suppression of the thy-
roid hormone axis also occur. This review examines and compares the eﬀects of four RXR-selective ligands: LGD1069, LG100268,
AGN194204, and LG101506, a selective RXR modulator. Similar to selective modulators of other nuclear receptors such as the
estrogen receptor (SERMs), LG101506 binding to RXR selectively maintains the desirable characteristic eﬀects of rexinoids while
minimizing the undesirable eﬀects. These recent ﬁndings suggest that, with continued research eﬀorts, RXR-speciﬁc ligands with
improved pharmacological proﬁlesmayeventually beavailable as additional treatmentoptionsforthecurrent epidemicofobesity,
insulin resistance, type 2 diabetes, and all of the associated metabolic sequelae.
Copyright © 2007 J. A. Pinaire and A. Reifel-Miller. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
The nuclear receptor (NR) family of transcription factors
(also referred to as the steroid/thyroid hormone receptor su-
perfamily) is quite large with approximately 150 proteins.
This large superfamily may be categorized into three sub-
groups: classic hormone receptors such as the glucocorti-
coid, estrogen, retinoic acid, thyroid hormone, and vita-
min D receptors; “sensor” receptors such as the peroxisome
proliferator-activated receptors (PPARs), the liver X receptor
(LXR), the farnesol X receptor (FXR), and the retinoid X re-
ceptor(RXR);andorphanreceptorssuchasapolipoproteinA-
I regulatory protein-1 (ARP-1) and chicken ovalbumin up-
stream promoter transcription factor (COUP-TF). In gen-
eral, these categories describe characteristics of ligand bind-
ing to these receptors. Ligands speciﬁc for the orphan recep-
t o r s ,i fa n ye x i s ta ta l l ,h a v en o tb e e ni d e n t i ﬁ e dt od a t e .C l a s -
sic hormone receptors bind speciﬁc ligands with high aﬃn-
ity. On the other hand, a broad range of lipophilic molecules
is thought to bind to the “sensor” receptors, generally with
broader speciﬁcity and lower aﬃnity as compared to hor-
mones that bind to the classical hormone receptors. The ma-
jority of the members of this family regulates transcription
of target genes by binding as homodimers or heterodimers
to speciﬁc DNA sequences, called hormone response ele-
ments (HREs) or nuclear receptor responsive elements (NR-
REs). For the classic hormone receptors and the sensor re-
ceptors, ligand binding induces (or stabilizes) DNA binding
and modulation of target gene transcription [1].
RXR is considered “promiscuous” because it forms het-
erodimerswithseveralotherfamilymembersthatcanbefur-
ther classiﬁed as permissive or nonpermissive binding part-
ners. Heterodimers formed by RXR and permissive binding
partners (PPARs, LXR, and FXR) can be activated by RXR-
speciﬁc ligands or by ligands speciﬁc for the binding part-
ner. Heterodimers formed by RXR and nonpermissive part-
ners (vitamin D and thyroid hormone receptors) can only be
activated by ligands speciﬁc for the partner, but not by lig-
ands speciﬁc for RXR [1]. However, recent evidence suggests
that the concept of NR “permissivity” may require reexami-
nation. For example, RXR has been considered a silent part-
ner in the RXR:TR heterodimer, yet recent data indicate that
this is not always true and the ability of RXR to inﬂuence
the activity of the heterodimer may depend on factors such
as tissue speciﬁcity, the cellular environment, or the ability
of various RXR ligands to recruit coactivator or corepressor2 PPAR Research
complexes to the region of the NRRE [2–4]. On the other
hand, the activity of the RXR:FXR heterodimer, previously
considered permissive, has recently been shown to be antag-
onized by ligand binding to RXR. These ﬁndings have led
to the term “conditionally permissive” in describing NR het-
erodimers containing RXR [5].
Recent reviews have highlighted the important role of
transcription and various transcription factor families, in-
cluding the NRs, in the regulation of intermediary me-
tabolism [1, 6]. Shulman and Mangelsdorf [7]r e c e n t l yr e -
viewed literature demonstrating that the metabolic syn-
drome could be treated by altering the activity of NR het-
erodimers containing RXR and partners PPAR, LXR, FXR,
and TR by using ligands speciﬁc for PPAR, LXR, FXR, and
TR. The aim of our review, on the other hand, is to sum-
marize available data suggesting that the metabolic syn-
drome could potentially be treated by altering the activity
of RXR homo- and heterodimers with rexinoids, a class of
compounds that bind selectively to RXR. We begin with an
overview of the metabolic syndrome, its strong association
with obesity and type 2 diabetes, and its prevalence. We then
focus on the metabolic eﬀects and potential therapeutic use
of RXR-selective ligands. The last section discusses the util-
ity and safety of these compounds for the treatment of the
metabolic syndrome.
2. THE METABOLIC SYNDROME
The metabolic syndrome (also called metabolic syndrome
X, syndrome X, insulin resistance syndrome, insulin resis-
tance/hyperinsulinemia syndrome, or metabolic cardiovas-
cular syndrome) has been extensively reviewed (see [8–11]
and references therein). Brieﬂy, insulin resistance is associ-
ated with a cluster of metabolic abnormalities that increases
the risk for type 2 diabetes, cardiovascular and renal dis-
eases, as well as some forms of cancer [8]. This cluster of
metabolic abnormalities is strongly associated with obesity,
predominantly visceral (abdominal) obesity, and physical
inactivity and includes the following: some degree of im-
paired glucose homeostasis, atherogenic dyslipidemia, hy-
pertension, an enhanced procoagulant state, and increased
expression of inﬂammatory markers. The relationship be-
tween obesity, insulin resistance, and cardiovascular disease,
recently reviewed by Reaven et al. [9]a n dG r u n d y[ 10], is
complicated, exempliﬁed by the fact that not all overweight
or obese individuals develop insulin resistance and its associ-
ated metabolic abnormalities. However, there is little doubt
that the increasing prevalence of overweight and obesity is
a fundamental contributor to the rising prevalence of the
metabolic syndrome (insulin resistance) and type 2 diabetes
[12–14].
In a recent review, Reaven [8]d i ﬀerentiated the terms
“insulin resistance syndrome” and “metabolic syndrome.”
The insulin resistance syndrome, according to Reaven, is a
term used to describe a cluster of metabolic abnormalities
and related outcomes that occur more commonly in insulin-
resistant/hyperinsulinemic individuals, and is not meant to
identify a speciﬁc clinical entity, nor does it refer to a speciﬁc
clinical diagnosis. On the other hand, the term “metabolic
syndrome” is more often considered a diagnostic tool use-
ful in the clinic for identifying individuals, presumably in-
dividuals who are insulin-resistant, who are at increased risk
forcardiovasculardiseaseandotherassociatedoutcomes.In-
deed,inaneﬀorttostandardizethediagnosticcriteriaforthe
metabolicsyndrome,deﬁnitionshaverecentlybeenputforth
by multiple national and international organizations: WHO
[15,16],ATPIII[17],ACE[18],IDF[19].Thedeﬁnitionsare
summarized in Table 1, and their utility and limitations have
been compared elsewhere [20]. The clinical measures used
in the deﬁnitions of the “metabolic syndrome” are typically
teststhatarefeasibleandrealisticforroutineclinicalpractice.
Using the ATP III criteria, the prevalence of the metabolic
syndrome has continued to increase among US adults from
28.0% as reported in the NHANES III (1988–1994) to 31.9%
in the NHANES 1999-2000 [21]. Most importantly, a re-
cent 2004 analysis revealed that the prevalence of metabolic
syndrome in US children and adolescents reached 38.7% in
moderately obese children and 49.7% in severely obese chil-
dren [22]. These data are sobering in light of the preva-
lence of metabolic syndrome reported in adolescents from
NHANES III (1988–1994), 6.8% among overweight adoles-
cents and 28.7% among obese adolescents [23].
Although the deﬁnitions for the clinical diagnosis of the
metabolicsyndromecontinuetoevolve,researchersandclin-
icians agree on the fundamental concept of the insulin resis-
tance/metabolic syndrome as a cluster of metabolic derange-
ments that increase risk for type 2 diabetes, cardiovascular
disease, renal disease, and other associated outcomes.
3. THE RETINOID-X-RECEPTOR
The NR family of transcription factors has been extensively
reviewed [1]. Brieﬂy, there are 3 RXR isotypes: RXRα,R X R β,
and RXRγ. Each isotype is encoded by a distinct gene, and
each gene is capable of generating at least 2 distinct tran-
scripts due to alternative promoter utilization and alterna-
tive splicing. The isotypes exhibit diﬀerent patterns of tissue-
speciﬁcexpression.RXRαisexpressedinliver,kidney,spleen,
placenta,andtheepidermis;RXRβ isexpressedubiquitously;
and RXRγ is expressed in skeletal muscle and cardiac muscle,
the anterior pituitary, and to a lesser extent in brain. Impor-
tantly, the pattern of tissue-speciﬁc expression varies widely
during development. The homology of the isotypes suggests
that these receptors regulate common target sequences and
respond to common ligands [24, 25].
Consistent with other members of the NR family, each
of the RXR isotypes has a modular domain structure [1, 24–
26].Themosthighlyconservedregion,regionC,istheDNA-
bindingdomaincontaining2zincﬁngermotifs,thehallmark
characteristic of members of this transcription factor fam-
ily. Region E, the second most conserved region, contains
the ligand binding domain (LBD), the primary dimerization
domain, and the ligand-dependent transcriptional activa-
tion function (AF-2). Furthermore, the LBD is the region of
the receptor that binds transcriptional corepressor or coac-
tivator complexes that mediate the eﬀect of the receptor onJ. A. Pinaire and A. Reifel-Miller 3
Table 1: Comparison of deﬁnitions of the metabolic syndrome.
Metabolic parameter WHO [15, 16] ATP III [17]A C E ‡ [18]I D F [ 19]
Elevated TG (mg/dL) ≥ 150 ≥ 150 ≥ 150
≥ 150 or treatment
for elevated TG
Low HDL-C∗ (mg/dL) < 39 (female)
< 35 (male)
< 50 (female)
< 40 (male)
< 50 (female)
< 40 (male)
< 50 (female) < 40 (male) or
treatment for low HDL-C
Elevated blood pressure
(mm Hg)
≥ 140/90 ≥ 130/85 ≥ 130/85
≥ 130/85 or treatment for
previously diagnosed HTN
Elevated fasting
glucose (mg/dL) — ≥ 110 110–125 ≥ 100 or previously
diagnosed diabetes
Elevated 2-hour post-
challenge glucose (mg/dL) —— > 140 —
Waist circumference∗
(cm) — > 88 (female)
> 102 (male) ——
Waist-to-hip ratio∗ > 0.85 (female)
> 0.90 (male) —— —
High BMI > 30kg/m2 —
Obesity is included in a list
of factors that increase the
likelihood of insulin
resistance∗∗
—
Microalbuminuria
≥ 20μg/min or
albumin-to-creatinine
ratio ≥ 30mg/g
—— —
Deﬁnition
Diabetes, impaired
fasting glucose, impaired
glucose tolerance, or
insulin resistance plus 2
or more of the above
Three or more of
the above
Risk factors∗∗ plus two or
more of the above
Central obesity
(ethnic-speciﬁc cut points)
≥ 94cm (female) ≥ 80cm
(male) plus two or more of
the above
Table modiﬁed from [12, 21]. Abbreviations: WHO, World Health Organization; ATP III, National Cholesterol Education Program Adult
Treatment Panel III; ACE, American College of Endocrinology; IDF, International Diabetes Federation; HTN, hypertension.
‡ ACE uses term “insulin resistance syndrome”
∗Gender-speciﬁc parameters
∗∗Risk factors include overweight (BMI > 25kg/m2 or waist circumference > 40 inches for men and > 35inches for women), sedentary
lifestyle, age > 40 years, non-Caucasian, family history of type 2 diabetes, hypertension, or cardiovascular disease, and personal history of
polycystic ovarian syndrome, gestational diabetes, acanthosis nigricans, or nonalcoholic steatohepatitis.
transcription. The N-terminal A/B region contains a ligand-
independent transcriptional activation function (AF-1). The
D region is the hinge domain, allowing the DNA binding
domain and the LBD to rotate. RXR homodimers and het-
erodimers bind to DNA targets comprised of 2 consensus
hexamermotifs,orhalfsites,suchasPuG(G/T)TCA(X),sep-
arated by a short spacer. The arrangement of these half sites
and the length of the spacing between them determine the
speciﬁcity of the response elements for RXR homo- or het-
erodimers [1, 24–26].
RXR has been shown to have diverse physiological func-
tions using RXR knockout (KO) mouse models (reviewed in
[24, 25]). Loss of RXRα results in much more severe pheno-
type than the loss of either RXRβ or RXRγ.L o s so fR X R α
function in the mouse germ line results in embryonic lethal-
ity (E13.5–16.5) due to defects of the cardiac ventricles and
placenta, as well as ocular abnormalities. Additional func-
tions of RXRα have been identiﬁed when the receptor has
been selectively deleted from speciﬁc tissues in mature an-
imals. Loss of RXRα function in adipose tissue results in
altered preadipocyte diﬀerentiation and resistance to obe-
sity, though this is thought to be attributable to the ab-
sence of functional RXRα/PPARγ heterodimers in adipose
tissue. Loss of RXRα function in skin results in multiple
phenotypic characteristics such as alopecia, hair follicle de-
generation, and dermal cysts, and although some of these
phenotypic characteristics are similar to the loss of func-
tion of the vitamin D receptor (VDR−/−), there are ab-
normalities in epidermal proliferation and diﬀerentiation
in the RXRα−/− model that are not accounted for in the
VDR−/− model. Loss of RXRα in the liver perturbs multi-
ple metabolic pathways mediated by LXRα,P P A R α,C A R β,
PXR, and FXR. Interestingly, many, but not all, of the de-
fects in lipid metabolism in liver-speciﬁc RXRα−/− mice are
similar to those in LXR−/− mice, suggesting that RXRα:LXR
plays an important role in hepatic lipid metabolism. The
phenotype of RXRα−/− in liver also shows similarities to
PPARα−/−mice,suggestingthatthephenotypeineachisat-
tributable to a loss of functional RXRα:PPARα heterodimers.
Furthermore, when RXRα is absent in the liver of adult mice,4 PPAR Research
the regenerative capacity of hepatocytes is impaired, and the
hepatocytes have a shorter lifespan compared to wild-type
animals. Absence of RXRα in prostate produces a marked al-
teration in the proﬁle of secretory proteins as well as preneo-
plastic lesions (reviewed in [24, 25]).
Loss of either RXRβ or RXRγ in the mouse germ line is
notembryoniclethal.Approximately50%ofRXRβ−/−mice
die before or at birth, but the animals that do survive appear
tobenormalexceptthatthemalesaresterile.RXRγ−/−mice
develop normally and appear similar to wild-type animals,
except they have higher serum T4 and TSH levels and higher
metabolic rates compared to wild-type animals (reviewed in
[24, 25]).
Because RXR has been shown to play a role in diverse
physiological processes including cell proliferation, diﬀeren-
tiation, and apoptosis and metabolism, RXR isotypes have
been referred to as “master regulators” [24, 25]. Therefore,
compounds that alter the activity of RXR also have the po-
tential to alter multiple physiological and metabolic path-
ways, with the potential of both beneﬁcial and deleterious
eﬀects.Indeed,inanimalmodelsofinsulinresistanceanddi-
abetes,rexinoidshavebeenshowntohavebeneﬁcialglucose-
lowering, insulin-sensitizing, and antiobesity eﬀects, while at
the same time raising triglyceride (TG) levels and suppress-
ing the thyroid hormone axis, side eﬀects that have limited
the development of these compounds as therapeutic agents
for the treatment of type 2 diabetes and insulin resistance. In
the following sections we review the metabolic eﬀects of four
diﬀerent rexinoids, one of which is a selective RXR modula-
tor.
4. EFFICACY OF REXINOIDS AS
THERAPEUTIC AGENTS
4.1. LGD1069(Bexarotene;Targretin,Ligand
PharmaceuticalsInc.,Calif,USA)
LGD1069 was the ﬁrst compound found to be a potent and
highly speciﬁc ligand for RXR [27]. LGD1069 has poor bind-
ing aﬃnity for RAR isoforms α, β,o rγ (Kd >1000nM for
all isoforms). On the other hand, LGD1069 binds with high
aﬃnity to RXR α, β,a n dγ:K dv a l u e sa r e1 4± 3, 21 ± 4, and
29 ± 7nM, respectively, see [28]. LGD1069 is used clinically
for the treatment of cutaneous T-cell lymphoma, though its
use for treating other cancers is currently being investigated
[29]. LGD1069 has been shown to lower glucose and insulin
levels in the ob/ob mouse to degrees similar to rosiglitazone
(ROSI) [30]. At 53 days of age, the average fasting glucose
and insulin concentrations in ob/ob mice are 262mg/dL and
12–18ng/ml, respectively. Over the course of 2 weeks, this
hyperglycemia and hyperinsulinemia continues to worsen.
Treatment of 53-day old female ob/ob mice with LGD1069
resulted in a 45% reduction of fasting plasma glucose (55%
reduction with ROSI) and a 30% reduction of fasting plasma
insulin (15% reduction with ROSI) [30]. Most of the pub-
lisheddataregardingLGD1069describeseﬀectsonlipidsand
TG, and that data is reviewed in following sections.
4.2. LG100268
As a selective ligand for RXR, LG100268 (LG268) has poor
binding aﬃnity for RAR isoforms α, β,o rγ (Ki >1000nM
for all isoforms). On the other hand, LG268 binds with high
aﬃnity to RXR α, β,a n dγ: Ki values are 3.2, 6.2, and 9.7nM,
respectively, see [31].
4.2.1. Effectsonglucoseandinsulinresistance
LG268 has also been shown to lower glucose and insulin
levels in the ob/ob mouse. Treatment of 53-day old female
ob/ob mice with LG268 for 2 weeks resulted in a 48% reduc-
tion of fasting plasma glucose (55% reduction with ROSI)
and a 59% reduction of fasting plasma insulin (15% reduc-
tionwithROSI)[30].Aglucose/insulintolerancetestshowed
signiﬁcant reductions of both the area under the glucose
curve and the area under the insulin curve with LG268, and
insulin resistance was reduced approximately 75% [30].
By the age of 16 weeks, the C57BL/KsJ strain of db/db
mice demonstrates a number of characteristics of progressed
type 2 diabetes and pancreatic β-cell dysfunction; compared
to 6-week old animals, serum insulin levels are nearly 10-
foldlowerandserumglucoselevelsandglycohemoglobinare
nearly doubled. Serum glucose, glycohemoglobin, and ﬁb-
rinogen, commonly elevated in insulin resistance, were re-
duced similarly by ROSI and LG268, and insulin content
in pancreatic islets increased signiﬁcantly with both com-
pounds. The eﬀects of ROSI and LG268 on body and or-
gan weights were compared. Between weeks 14 and 16, mean
body weight change in vehicle-, ROSI-, and LG268-treated
animals was −2.7, +3.2, and +0.5g r a m s ,r e s p e c t i v e l y .U n -
like ROSI, LG268 did not induce adipose tissue hypertrophy.
Furthermore, LG268 produced several eﬀectson the liver not
observed with ROSI: hepatomegaly, increased peroxisome
number, fatty inﬁltration, and induced expression of mi-
crosomal lauric acid hydroxylase. Therefore, compared with
ROSI, LG268 had very similar eﬀects on glucose-lowering,
pancreatic insulin content, and serum ﬁbrinogen levels, but
distinctly diﬀerent eﬀects on body weight and liver, eﬀects
likely mediated via the RXR:PPARα pathway [32].
To further distinguish the mechanism of rexinoids as
glucose-lowering and insulin sensitizing compounds from
that of TZDs, Ahuja et al. examined the eﬀect of LG268 on
mRNA levels of three TZD-inducible genes shown to con-
tain a PPRE for the RXR:PPARγ heterodimer: mitochondrial
carnitine palmitoyl transferase (MCPT), steroyl coenzyme A
desaturase 1 (SCD1), and fatty acid translocase (FAT). Mes-
sage levels were compared in adipose tissue, skeletal muscle,
andliver.Tosummarize,bothcompoundsinducedmRNAof
all three genes: ROSI induced message levels in adipose tis-
sue and LG268 induced the mRNAs in liver. The compounds
hadsimilaractionsinskeletalmuscle.Similartowhatwasre-
ported by Lenhard et al. [32], ROSI and LG268 have similar
eﬀects on glucose-lowering, though their mechanisms may
be quite distinct. The authors concluded that rexinoids do
not function as simple “TZD mimetics” in vivo, as previ-
ously suggested, and though the RXR:PPAR heterodimer hasJ. A. Pinaire and A. Reifel-Miller 5
been shown to be permissive using in vitro transfection ex-
periments with synthetic reporter constructs, rexinoids have
a pharmacological proﬁle distinct from TZDs [33].
To further investigate how rexinoids and TZDs diﬀer in
mediating their glucose-lowering and insulin-sensitizing ef-
fects, Shen et al. compared the eﬀects of ROSI and LG268
on insulin signaling in muscle of db/db mice [34]. As re-
ported by the other studies, ROSI and LG268 had similar ef-
fects on glucose-lowering. However, ROSI and LG268 were
demonstrated to have distinctly diﬀerent eﬀects on compo-
nents of the insulin signaling pathway in muscle. In quadri-
cep, neither compound had any eﬀect on insulin receptor
mRNA or protein levels, or on insulin receptor tyrosine
phosphorylation. However, while ROSI increased expression
(mRNA and protein) of c-Cbl-associated protein (CAP),
LG268 induced insulin-stimulated tyrosine phosphorylation
of the insulin receptor substrate-1 (IRS-1). In extensor dig-
itorum longus (EDL) muscle, ROSI induced both basal and
insulin-stimulated tyrosine phosphorylation of C-Cbl, while
LG268 induced insulin-stimulated Akt phosphorylation. In
addition, LG268 suppressed IRS-1 Ser307 phosphorylation,
which has been implicated in insulin resistance. Taken to-
gether,thesedataprovidedclearevidencethatTZDsandrex-
inoids exert their eﬀects through diﬀerent mechanisms. In
muscle, TZDs mediated their eﬀects through the CAP/c-Cbl
pathway, and rexinoids exerted their eﬀects through the IRS-
1/Akt pathway, suggesting that LG268 does not mediate its
eﬀectsinmuscleviabindingtotheRXR:PPARγ heterodimer.
Although LXR ligands have eﬀects similar to rexinoids, the
authors point out that this too is unlikely because LXR lig-
ands had no eﬀect on Akt phosphorylation in these animals.
Therefore, the authors speculate that LG268 may mediate
its eﬀects in muscle through PPARα or PPARδ, or possibly
through the RXR:RXR homodimer [34].
4.2.2. Effectsonobesity
Three studies using the Zucker fatty rat model have demon-
strated antiobesity eﬀects of rexinoids [35–37]. Emilsson et
al. compared the eﬀects of ROSI and LG268 on food con-
sumption, body weight, and the expression of uncoupling
protein (UCP) isoforms UCP-1, UCP-2, and UCP-3 [37].
ROSI signiﬁcantly increased food consumption, but had no
signiﬁcant eﬀect on body weight change. In contrast, LG268
signiﬁcantly decreased food consumption and body weight.
UCP-1 mRNA in brown adipose tissue (BAT) was signiﬁ-
cantlyinducedbyLG268,butnotbyROSI.NeitherROSInor
LG268hadanyeﬀectonUCP-2mRNAinBAT,whiteadipose
tissue (WAT), muscle, or brain. UCP-3 mRNA was induced
by ROSI and LG268 in BAT and WAT, but in muscle only
ROSIinducedUCP-3.Thus,intheZuckerfattyrat,rexinoids
have antiobesity eﬀects, whereas TZDs do not. Furthermore,
the authors speculated that LG268 may promote thermogen-
esis due to the upregulation of UCP-1 in BAT [37].
Tofurtherinvestigatethemechanismsunderlyingthean-
tiobesity eﬀects of rexinoids, Ogilvie et al. [36]e v a l u a t e d
body weight and cumulative food consumption over 42 days
in female Zucker fatty rats treated with ROSI or LG268.
LG268 signiﬁcantly reduced body weight and cumulative
foodconsumptionwhereasROSIincreasedbothbodyweight
andconsumedfood.Bodycompositionanalysisrevealedthat
ROSI increased fat mass, but LG268 reduced fat mass in both
fatty and lean animals. Neither compound had an eﬀect on
leanbodymass.TheeﬀectsofROSIandLG268onadipogen-
esis and apoptosis in subcutaneous and mesenteric (ovarian)
fat were compared. In ovarian fat, there was no diﬀerence
between ROSI and LG268 in their eﬀects on apoptosis and
adipogenesis. In contrast, in subcutaneous fat, LG268 more
strongly induced apoptosis and was a weaker inducer of adi-
pogenesis compared with ROSI, suggesting that the LG268-
mediated reduction of fat mass was at least in part due to
increasedapoptosisinsubcutaneousadiposetissue.Todeter-
mine whether decreased food consumption and body weight
observed with LG268 treatment was due to adverse toxico-
logical eﬀects, dynamic feeding behavior before, during, and
after treatment with LG268 was examined. The authors hy-
pothesizedthatifLG268hadadversetoxicologicaleﬀects,the
animals would forgo meals (decreased meal frequency); on
the other hand, if LG268 truly had antiobesity properties,
theanimalswouldbecomesatiatedafterconsuminglessfood
(decreased food consumption). Indeed, LG268 was associ-
atedwithdecreasedmealsize.Finally,becauseRXRispresent
in hypothalamic satiety centers, the authors tested whether
LG268 acts centrally in the brain. Injection of LG268 directly
into the cerebral ventricles produced reductions of cumula-
tive body weight gain and daily food consumption similar to
that observed with oral administration of LG268, suggesting
that LG268 mediated its antiobesty eﬀects through the cen-
tralnervoussystem.Mostsurprisingwastheobservationthat
theTG-raisingeﬀectofLG268(discussedingreaterdetailbe-
low) was abolished with ICV administration. These observa-
tions led the authors to conclude that LG268 not only reg-
ulates feeding behavior and body weight in a manner com-
pletely distinct from TZDs, through the central nervous sys-
tem, but that the antiobesity action of rexinoids may be sep-
arable from its eﬀects on TG [36].
4.3. AGN194204
As a selective ligand for RXR, AGN194204 has poor binding
aﬃnity for RAR isoforms α, β,o rγ (Kd > 30K nM for all
isoforms). On the other hand, AGN194204 binds with high
aﬃnitytoRXRα,β,andγ:Kdvaluesar e0.4,3.6,and3.8nM,
respectively, see [38].
4.3.1. Effectsonglucoseandinsulinresistance
Li et al. [39] examined the metabolic eﬀects of AGN194204
in female Zucker diabetic fatty rats (ZFF rats). After being
fed a high-fat diet (48% fat and 16% protein) for 3-4 weeks,
these animals were treated with troglitazone (TROG) or
AGN194204.AGN194204andTROGhadverysimilareﬀects
on lowering serum glucose and insulin. A hyperinsulinemic-
euglycemic clamp indicated that the insulin-sensitizing ef-
fects of AGN194204 occurred predominantly in the liver,
while TROG exerted its insulin-sensitizing eﬀect in the liver6 PPAR Research
Table 2: Summary of the eﬀects of RXR-speciﬁc ligands on glucose, insulin resistance, and obesity.
RXR ligand Eﬀects on glucose
[references]
Eﬀects on insulin or
insulin resistance
[references]
Eﬀects on body weight
[references] Eﬀects on insulin signalling [references]
LGD1069 ↓ [30] ↓ [30] No change [30]
LG100268 ↓ [30, 32–34, 40, 41] No change [32]
↓ [30, 33–36, 40]
No change [30, 32, 34]
↓ [35–37, 40]
IRS-1/Akt pathway and decreased
IRS-1 Ser307 phosphorylation in
muscle [34]
AGN194204 ↓ [39] ↓ [39] No change [42];
↑ [39]
↑ IRS-2 protein expression before and
after insulin treatment; increase in
insulin-stimulated Akt phophorylation in
liver [39]
LG101506 ↓ [40] ↓ [40] No change [40]
and in peripheral tissues. The eﬀects of AGN194204 and
TROG on components of the insulin signaling pathway
in liver and skeletal muscle were compared. In liver,
AGN194204 increased IRS-2 protein levels before and af-
ter treatment with insulin, and increased insulin-stimulated
Akt phosphorylation following insulin treatment. In skele-
tal muscle, TROG stimulated Akt phosphorylation and pro-
duced a small but consistent increase in IRS-1 protein before
and after insulin treatment. These results are consistent with
liver being the primary target of insulin-sensitizing eﬀect of
AGN194204, and with skeletal muscle being an important
target of the insulin-sensitizing eﬀects of TROG.
4.4. LG101506
LG101506 (LG1506) has poor binding aﬃnity for RAR iso-
forms α, β,o rγ: Ki values are 2746 ± 395, 3516 ± 420, and
> 10000nM, respectively. On the other hand, LG1506 binds
with high aﬃnity to RXR α, β,a n dγ:K iv a l u e sa r e3 .0 ± 0.8,
9.0 ±1.7, and 11.0 ±3.6, respectively, see [40].
4.4.1. Effectsonglucoseandinsulinresistance
Unlike other RXR-selective ligands, LG1506 binding to the
RXRreceptorinducesaconformationthatresultsinselective
activation of RXR:PPARγ, RXR:PPARα, and RXR:PPARδ,
but not RXR:RAR, RXR:LXR, or RXR:FXR heterodimers
[40]. The glucose-lowering and insulin-sensitizing eﬀects of
LG1506 were comparable to those of LG268 and ROSI in the
femaleZuckerfa/farat.However,whenadministeredasasin-
gle agent, LG1506 had no signiﬁcant eﬀect on body weight,
while,asreportedpreviously,bodyweightwasincreasedwith
ROSI and decreased by LG268. When coadministered, how-
ever, LG1506 completely blocked the weight gain observed
with ROSI.
4.5. Summaryoftheeffectsofrexinoidsonglucose,
insulinresistance,andobesity
The eﬀects of RXR-speciﬁc ligands on glucose, insulin re-
sistance, and obesity are summarized in Table 2.R e v i e w
of the literature describing the antidiabetic eﬀects of rexi-
noids shows that RXR-selective ligands do not mediate their
glucose-lowering and insulin-sensitizing eﬀects by merely
“mimicking” the eﬀects of TZDs. Initially thought to syner-
gizetheactionsofTZDsthroughbindingtotheRXRcompo-
nent of the RXR:PPARγ heterodimer, recent evidence clearly
demonstrates that these two classes of compounds mediate
their actions via distinct mechanisms. Both Shen et al. [34]
andLietal.[39]havedemonstratedthatrexinoidsandTZDs
act through distinct pathways of insulin signaling. In addi-
tion, while both rexinoids and TZDs remodel adipose tissue,
rexinoids have antiobesity properties whereas TZDs have the
opposite eﬀect. Futhermore, Ogilvie et al. [36]h a v ed e m o n -
strated that the rexinoid LG268 mediates its antiobesity ef-
fects through the central nervous system. While the rexinoid
LG1506 was shown to be weight-neutral when administered
as a single agent in the Zucker fa/fa rat model [40], it com-
pletely blocked weight gain when coadministered with ROSI.
Therefore, compared to TZDs, glucose-lowering, insulin-
sensitizing agents currently used for the treatment of insulin
resistance and type 2 diabetes, the rexinoids, with further de-
velopment, may eventually oﬀer the advantage of promoting
weightloss,thoughbeingweight-neutralwouldbeanadvan-
tage over TZDs. Furthermore, if rexinoids were to be used in
combination with TZDs, this may oﬀer even greater eﬃcacy
and limit the weight gain characteristic of TZDs.
5. SAFETY OF REXINOIDS AS THERAPEUTIC AGENTS
5.1. Elevationoftriglyceridelevels
Plasma triglyceride levels are maintained at normal levels in
fasted animals due to the established equilibrium between
the rate of hepatic secretion of very low density lipoproteins
(VLDL) versus the rate of VLDL clearance. VLDL particles
are cleared by lipoprotein lipase (LPL) activity present in the
tissue vascular beds and hepatic lipase present in the liver
[43].
Hypertriglyceridemiawasinitiallyseeninpatientsreceiv-
ing retinoic acid isomers that are known to activate both
RARs and RXRs. Administration of RAR-speciﬁc retinoids
results in hypertriglyceridemia in rodents [44] and in hu-
mans [45]. Similarly, patients in a phase I clinical trial for ad-
vancedcancertreatedwiththeRXR-selectiveagonistLG1069
experienced elevated triglyceride levels [46, 47].J. A. Pinaire and A. Reifel-Miller 7
5.2. LGD1069
Recent studies have investigated the physiological and mo-
lecular bases of the hypertriglyceridemia associated with
LGD1069 treatment [41, 48, 49]. Treatment of ZDF rats with
a broad range of LGD1069 doses (0.3, 1, 3, 10, or 30mg/kg)
for 14 days produced a nearly linear dose-dependent in-
crease in serum TG levels, with no change in total choles-
terol levels. Lipoprotein proﬁle analysis revealed no signiﬁ-
cantchangeintheIDLorLDLfractionswithLGD1069treat-
ment, and no signiﬁcant change in the HDL fraction, though
HDL particles were less heterogeneous and more bulky rela-
tive to control. However, LG1069 signiﬁcantly increased the
VLDLfraction.TheauthorsinvestigatedwhetherLG1069re-
duced VLDL clearance by aﬀecting lipoprotein lipase (LPL).
LPL activity was potently suppressed by LG1069 in heart and
skeletal muscle, with skeletal muscle being the most sensi-
tive. Importantly, this suppression of LPL activity in skele-
tal muscle and cardiac tissue did not correspond to reduced
LPL mRNA levels, as LG1069 had no eﬀects on LPL mRNA
levels in either tissue. On the other hand, LG1069 had no ef-
fect on LPL mRNA or activity in adipose tissue. The authors
proposed that the hypertriglyceridemia observed in LG1069-
treated animals was due to elevated VLDL caused by a pri-
mary defect in LPL-dependent catabolism. Furthermore, the
authors speculated that skeletal muscle in particular may be
an important rexinoid target tissue [41].
In contrast, when Ouamrane et al. [48]t r e a t e dm a l e
C57BL/6J mice with LGD1069 or fenoﬁbrate, no eﬀect of
LGD1069 on serum TG levels was observed. As expected,
fenoﬁbrate decreased serum TG approximately 50%, and
no change in serum cholesterol was observed with ei-
ther treatment. When this experiment was repeated using
age-matched male PPARα-deﬁcient mice (C57BL/6J back-
ground), LG1069 increased serum TG levels approximately
3-fold and the TG-lowering eﬀect of fenoﬁbrate was abol-
ished. To further examine the involvement of PPARα in the
eﬀects of LGD1069, the ability of LGD1069 to induced hep-
atomegaly was examined, as was the ability of LGD1069 to
induce mRNA of genes known to be responsive to peroxi-
some proliferators (PPs): CYP4A (cytochrome P450 4A) and
PDK4 (pyruvate dehydrogenase kinase 4). In wild-type an-
imals, LG1069 and fenoﬁbrate induced CYP4A mRNA and
hepatomegaly.InPPARα-deﬁcientanimals,theabilityoffen-
ﬁbrate to induce hepatomegaly was lost while the ability of
LG1069 to induce hepatomegaly remained intact, though
both fenoﬁbrate and LG1069 failed to induce CYP4A in liver.
In wild-type animals, LG1069 induced PDK4 mRNA in both
heart and kidney, whereas LGD1069 induced PDK4 mRNA
only in the heart tissue of PPARα-deﬁcient animals. These
observations led the authors to propose that rexinoids such
as LGD1069 mediate their physiological eﬀects through both
PPARα-dependent pathways (induction of CYP4A mRNA in
liver and PDK4 mRNA in kidney) and PPARα-independent
pathways (hepatomegaly and induction of PDK4 mRNA in
cardiac tissue). Still, the exact mechanism explaining why
LGD1069 increased serum TG by 3-fold in the PPARα-
deﬁcient animals and not at all in the wild-type animals
remained unclear. The authors speculated that two separate
pathways may account for the eﬀects of LGD1069 on serum
TG in this animal model: a PPARα-independent pathway
may account for the TG-raising eﬀect of LGD1069, while
aP P A R α-dependent pathway would decrease serum TG via
activation of the RXR:PPARα heterodimer. Thus, TG levels
in the wild-type animal would reﬂect the relative activity of
both pathways [48].
Although LGD1069 elevates serum TG in ZDF rats, very
recent data demonstrate that LGD1069 inhibits atheroscle-
rosis progression in the apolipoprotein E2 knockin (Apo E2-
KI) mouse model [49]. Compared with the Apo E knock-
out (KO) model, which is characterized by isolated hyper-
cholesterolemia, the Apo E2-KI mouse model develops a
mixed dyslipidemia (elevated TG and hypercholesterolemia)
more commonly found in humans. Female Apo E2-KI mice
(C57BL6 background) were fed a Western-style diet (0.2%
cholesterol and 21% fat) supplemented with or without
LG1069 (0.018%wt/wt) for 11 weeks. Oil-Red-O staining
of atherosclerotic lesions in the aorta demonstrated that
LGD1069treatmentsigniﬁcantlyreducedlesionarea,though
LGD1069increasedplasmaTGconcentrationsover50%.TG
was associated with the VLDL fraction and LGD1069 pro-
duced a signiﬁcant reduction of plasma total cholesterol that
correspondeds to a reduction in non-HDL-C (IDL and LDL
cholesterol). LGD1069 signiﬁcantly decreased plasma Apo
B, though no change in liver Apo B mRNA was observed.
Furthermore, LGD1069 signiﬁcantly induced LDL receptor
mRNA in liver (approximately 2-fold). LGD1069 was also
shown to signiﬁcantly decrease intestinal cholesterol absorp-
tion, as evidenced by reduced mRNA levels of Niemann-Pick
C1-Like1 (NPC1L1) and CD13, genes recently identiﬁed as
critical components of the intestinal cholesterol absorption
machinery, and ABCA1 in both duodenum and jejunum.
LGD1069 also signiﬁcantly increased ABCA1 and ABCG1
mRNA levels in the aortic sinus. Peritoneal macrophages
obtained from control Apo E2-KI mice showed signiﬁ-
cant lipid accumulation; however, LGD1069 treatment pre-
vented lipid accumulation in vivo and signiﬁcantly enhanced
Apo AI- and HDL-mediated cholesterol eﬄux from these
macrophages in vitro. Although the mechanism(s) through
which LGD1069 exerts these eﬀects remains unclear, the au-
thors suggest that the RXR:LXR pathway may play an impor-
tant role, but emphasize that LGD1069 may selectively oper-
ate through RXR:LXR in a tissue-speciﬁc and gene-speciﬁc
manners. In contrast to the ZDF rat model [41], these results
suggest that LGD1069-mediated hypertriglyceridemia in the
Apo E2-KI mouse model is countered by a decrease in non-
HDL cholesterol (IDL and HDL), a corresponding increase
in hepatic LDL receptor mRNA, decreased intestinal choles-
terol absorption, and increased Apo A- and HDL-dependent
cholesterol eﬄux [49].
5.3. LG100268
StudiesoftheeﬀectsofLG268onTGarediﬃculttointerpret
due to conﬂicting results. Studies using db/db mice showed
that LG268 lowers TG [30, 32, 34, 50] while a study using8 PPAR Research
ZDF rats showed that LG268 increases TG [41]. Mukherjee
demonstrated that gemﬁbrozil and LG268, as single agents,
signiﬁcantly reduced plasma TG, while coadministration
produced an additive reduction. Similarly, genﬁbrozil and
LG268 each increased plasma HDL-C levels, while coadmin-
istration produced an additive increase. The authors con-
cluded that the RXR:PPARα heterodimer was the common
target of genﬁbrozil and LG268 in TG-lowering and HDL-
raising [50]. In a separate study, Mukherjee et al. [30] sug-
gested that the RXR:PPARγ heterodimer was the common
target of ROSI and LG269 in TG-lowering. ROSI and LG268,
as single agents, signiﬁcantly reduced serum TG, though
coadministration produced an additive decrease [30]. In
contrast, Lenhard et al. reported that although ROSI and
LG268 displayed similar eﬀects on reducing serum glucose
and glycohemoglobin in db/db mice with progressed pan-
creatic β-cell dysfunction, LG268 lowered TG, but not as po-
tently as ROSI [32]. This suggested that the TG-lowering ef-
fects of LG268 in these animals were not mediated by the
RXR:PPARγ heterodimer [32]. To further investigate these
discrepant results, Davies et al. [41] treated ZDF rats with
either ROSI or LG100268 for 14 days. ROSI maximally de-
creased serum TG levels at day 3, while LG268 steadily in-
creased TG levels throughout the treatment period. When a
single dose of LG268 was administered to nonobese, non-
diabetic Sprague Dawley rats, after a lag period of 60 min-
utes, serum TG rose rapidly and remained elevated for ap-
proximately 6 hours before returning to normal by 24 hours.
The LG268-mediated TG increase was abolished by pretreat-
ment with actinomycin D. Post-heparin plasma LPL activ-
ity was signiﬁcantly decreased 3 hours after administration
of the single LG268 dose. To further characterize the eﬀect
of LG268 on LPL activity, C2C12 diﬀerentiated mouse my-
ocytes were stably transfected with an LPL expression vector.
In vitro LPL activity was potently suppressed by LG268 and
this suppression was abolished by cotreatment with actino-
m y c i nD .F u r t h e r m o r e ,i nv i t r oL P La c t i v i t yw a sn o ts u p -
pressed by WY14,643 or ROSI, suggesting that LG268 me-
diates these eﬀects via pathways distinct from PPARα and
PPARγ [41].
5.4. AGN194204
The rexinoid AGN194204 signiﬁcantly increased serum TG
concentrations while TROG decreased TG in female Zucker
diabetic fatty rats (ZFF) [39]. A time course examining the
eﬀect of AGN194204 on serum TG demonstrated that TG
levels are induced by AGN194204 approximately 3-fold after
only 1 day of treatment and remain elevated at that level un-
til day 3. By day 7, serum TG levels have begun to decrease
to levels less than 2-fold control. Liver TG content increases
less than 2-fold with AGN194204, and those levels remain
stable throughout a 7-day treatment period. Aﬀymetrix gene
chips were utilized to gain further insight into the metabolic
actions of AGN194204. Mice were treated with vehicle or
AGN194204 and total liver RNA hybridized to the chip. As
described in detail in [39], the data were analyzed using a
web-based expression analysis program. To summarize, two
gene expression networks were found to be signiﬁcantly al-
tered in response to treatment with AGN194204. One net-
work centered on the increased expression of SREBP-1c and
genes such as FAS, ACO, 3-keto-CoA thiolase, and FABP; the
secondnetworkconsistedofgenescontainingG-proteinsub-
units coupled to the glucagon receptor as well as to FoxA.
Glucagon receptor mRNA levels in liver did not change in
response to either AGN194204 or TROG treatment, how-
ever, FoxA2 and FoxA3 mRNA levels were signiﬁcantly re-
duced in liver following treatment with AGN194204. Based
on these ﬁndings, the authors speculated that at least one
mechanism explaining AGN194204-mediated hypertriglyc-
eridemia (in addition to the possibility of AGN194204 acti-
vatingtheRXR:LXRheterodimer)couldbetheAGN194204-
mediated increase of IRS-2 and decrease of FoxA2 in liver.
FoxA2 increases the expression of fatty acid oxidizing en-
zymesintheliver,andinsulininhibitsFAoxidationinpartby
sequesteringFoxA2inthecytoplasm.Therefore,AGN194204
treatment would ultimately inhibit fatty acid oxidation and
increase SREBP-1c and other enzymes involved in de novo
TG synthesis.
5.5. LG101506
Compared with LG268, which potently induced TG in
nonobese, nondiabetic Sprague Dawley rats, LG1506 had no
eﬀect on TG levels [40]. TG levels were signiﬁcantly ele-
vated 2 hours after administration of a single dose of LG268,
whereas TG levels were similar to control 2 hours after treat-
ment with LG1506. In Zucker fa/fa rats, similar results were
observed in that levels that were potently induced by LG268
overa14-daytreatmentperiod,andTGlevelswereincreased,
thoughnotsigniﬁcantly,bytreatmentwithLG1506.Interest-
ingly, the greatest eﬀectof LG1506 on TG levels was observed
at a lower dose of 3mg/kg, and this eﬀect was most evident
on day 7. This curious observation was further investigated
in lean and obese Zucker rats treated with 1, 3, or 30mg/kg
LG1506 for 7 days. Indeed, low doses (1 and 3mg/kg) of
LG1506 induced TG by day 3 in both lean and obese ani-
mals with maximal elevations at day 7, while TG levels after
treatment with higher doses of LG1506 (30mg/kg) remained
similar to control levels for the duration of the treatment pe-
riod. These ﬁndings led the authors to speculate that LG1506
may aﬀect multiple pathways that regulate TG metabolism:
pathways that increase TG levels at low doses of LG1506 and
pathways that oppose the TG-raising eﬀects at higher doses
ofLG1506.Theauthorsaddthatthecomplexityoftheeﬀects
of LG1506 on TG requires further investigation before agents
suchasLG1506canbeusedforthetreatmentofinsulinresis-
tance and type 2 diabetes, however, progress has been made
in developing RXR-selective agonists that maintain glucose-
loweringpropertieswiththepotentialtominimizeunwanted
side eﬀects.
5.6. Suppressionofthethyroidhormoneaxis
Regulation of thyroid hormone levels is the result of a com-
plex interaction involving the hypothalamic-pituitary-thy-
roid axis. Thyroid-stimulating hormone (TSH), also knownJ. A. Pinaire and A. Reifel-Miller 9
Table 3: Summary of the eﬀects of RXR-speciﬁc ligands on hypertriglyceridemia and suppression of the thyroid hormone axis.
RXR ligand Eﬀects on triglycerides [references] Eﬀects on thyroid hormone axis [references]
LGD1069
No change in PPARα WT mice;
↑ in PPARα−/− mice [48]
↓ [50]
↑ [41, 49]
Human data: ↑ ([ 46, 47, 51]; reviewed in [29])
Human data: ↓ ([47, 51, 52]; reviewed in [29])
LG100268
No change [44]
↓ [30, 32, 34, 50]
↑ [36, 40, 41]
Note that [36] shows increased TG with oral
administration but not with
intracerebroventricular administration
↓ [36, 40, 53, 54]
Note that [36] shows thyroid hormone axis
suppression with oral administration but not with
intracerebroventricular administration.
References [53, 54] investigate the mechanism of
suppression of thyroid hormone axis by rexinoids
AGN194204 ↑ [39, 42] ↓ [42]
LG101506
No change in Sprague Dawley rats; ↑ at low
doses and no change at higher doses in
Zucker rats, with eﬀects most evident on day
7 of a 14-day treatment period [40]
No change in either Sprague Dawley or Zucker
rats [40]
as thyrotropin, is a glycoprotein hormone that stimulates de-
velopment of the thyroid gland and also its secretory activity.
Thyrotropin-releasing hormone (TRH) is produced by the
hypothalamus and triggers TSH release from the anterior pi-
tuitary. TSH release is inhibited by negative feedback exerted
by rising blood levels of thyroid hormone acting on both the
pituitary and the hypothalamus. Thyroid hormone is actu-
ally two active iodine-containing hormones, thyroxine (T4)
and triiodothyronine (T3). Thyroxine is the major hormone
secretedbythethyroidgland,withthemajorityofT3formed
at the target tissue by conversion of T4 to T3 [55].
The relationship between alterations in thyroid hormone
levels and retinoid administration has been known for many
years. In 1947, Simkins described the use of high doses of vi-
tamin A (retinol) for the treatment of hyperthyroidism [56].
Through extensive conversion in vivo, retinol is modiﬁed to
retinaldehyde,all-transretinoicacid,andﬁnally13-cisand9-
cis retinoic acid, which are known to activate genes through
the RAR and RXR pathways. Many years later, central hy-
pothyroidismwithsigniﬁcantsuppressionofserumTSHlev-
els was noted in patients with refractory or persistent early-
stage cutaneous T-cell lymphoma following treatment with
the synthetic RXR-selective retinoid LG1069 [51, 52].
The mechanism for RXR-induced thyroid hormone al-
terations was investigated in preclinical studies using the
RXR-selective ligands, LG268 and AGN194204. After a sin-
gle administration of LG268 to Sprague Dawley rats, a rapid
and statistically signiﬁcant decrease in TSH levels was seen
acutely, 0.5 to 1 hour after treatment. In contrast, total T3
and T4 levels declined more gradually reaching statistical
signiﬁcance 24 hours after compound administration. Fur-
ther studies investigating the mechanism for TSH suppres-
sion showed that neither TSHb mRNA nor TSH protein
levels were altered; however, LG100268 treatment reduced
TRH-stimulatedTSHsecretionby54%[53].Similarﬁndings
were seen with another high aﬃnity RXR-selective ligand,
AGN194204. When administrated to female Zucker rats and
nondiabeticlittermates,AGN194204decreasedTSHlevelsby
70–80%, which was followed by a decrease in T3 and T4 lev-
els. In diabetic mice, AGN194204 caused a time-dependent
decrease in TSH levels after one day of treatment proceeding
the fall in T4 levels that was signiﬁcant at three days after the
initiation of treatment [42]. More recent studies with LG268
in mice and using a thyrotrope-derived cell line showed that
rexinoids directly suppress TSH secretion, TSHβ mRNA lev-
els, and promoter activity, but no direct eﬀect on hypotha-
lamic TRH levels was seen. These studies also demonstrated
that any of the RXR isotypes (α,β,orγ) can mediate TSH
suppression by rexinoids, but the RXRγ i s o t y p ei sm o s te ﬃ-
cient at mediating this response [54].
5.7. Summaryoftheeffectsofrexinoidson
hypertriglyceridemiaandsuppressionof
thethyroidhormoneaxis
The eﬀects of RXR-speciﬁc ligands on hypertriglyceridemia
and suppression of the thyroid hormone axis are summa-
rized in Table 3. By reviewing the literature investigating
the eﬀects of rexinoids on lipids, particularly hypertriglyc-
eridemia, it is clear that these compounds have diverse and
complex eﬀects; furthermore, the ability of rexinoids to
lower or raise TG levels may depend on a number of fac-
tors, including species and strain of the animal model used
and the characteristics of the individual ligand. For exam-
ple, LG1069 increased TG in the ZDF rat [41], had no ef-
fect on TG levels in the C57BL/6J mouse [48], and in-
creased TG levels signiﬁcantly in the apoE2-KI mouse model
[49]. Interestingly, using the apoE2-KI model, Lalloyerc et
al.demonstratedthat LG1609signiﬁcantlyinhibited the pro-
gression of atherosclerosis despite TG levels being increased
over 50% [49]. In addition to LG1069 signiﬁcantly reducing
atherosclerotic lesion area in the apoE2-KI model, the rex-
inoid also resulted in a number of additional beneﬁcial ef-
fects on lipid metabolism: signiﬁcant reduction of non-HDL10 PPAR Research
cholesterol, reduction of plasma apoB levels, induction of
hepaticLDLreceptors,reducedintestinalcholesterolabsorp-
tion, and enhanced apoAI- and HDL-mediated cholesterol
eﬄux. These ﬁndings prompted a rather controversial spec-
ulation by the authors: perhaps elevated TG, long thought to
be an independent risk factor for cardiovascular disease, may
not increase the risk for cardiovascular disease when asso-
ciated with a concomitant decrease in non-HDL cholesterol.
LG268wasshowntoconsistentlylowerTGinthedb/dbmice
model and increase TG in ZDF rat [30, 32, 34, 41, 50]. Li
et al. showed that AGN194204 increased TG levels in ZFF
rats [39], and speculated on the mechanism of AGN194204-
mediated hypertriglyceridemia by using data obtained from
Aﬀymetrix gene chip analysis. Finally, Leibowitz et al. pro-
vided data on LG1506, a selective RXR modulator that pref-
erentially activates RXR heterodimers with PPARα,P P A R γ,
and PPARδ [40]. LG1506 was shown to increase TG at low
doses while having no eﬀect on TG levels at higher doses that
are eﬃcacious for the antidiabetic eﬀects of LG1506.
Suppression of the thyroid hormone axis has been ob-
servedinpatientsreceivingLG1609forthetreatmentofcuta-
neous T-cell lymphoma [51, 52]. The mechanism of LG268-
mediated hypothyroidism was investigated in the rat [53]
and mouse [54]. Sharma et al. [54] report that LG268 ex-
erts multiple eﬀects on the hypothalamic-pituitary-thyroid
axis, and Ogilvie et al. [36] demonstrated that hypertriglyc-
eridemia and suppression of the HPT axis are separable from
eﬀects on body weight and food intake. Whether adminis-
tered orally or ICV, LG268 reduced food intake and body
weight; on the other hand, LG268 only increased TG lev-
els and suppressed total T4 levels when administered orally.
Macchia et al. [42] demonstrated that AGN194204 caused
central hypothyroidism independently of TR, the main me-
diator of hormone-induced TSH suppression. Finally, Lei-
bowitz et al. [40] showed that suppression of the HPT
axis could be minimized with the selective RXR modulator,
LG1506.
6. FUTURE DIRECTIONS
The number of individuals with obesity and type 2 diabetes
is growing at epidemic rates, reaching younger populations
and expanding into newly emerging industrialized nations.
RXR-speciﬁc ligands have potent glucose-lowering, insulin-
sensitizing, and antiobesity eﬀects in animal models of obe-
sity, insulin resistance, and type 2 diabetes. As the mecha-
nisms underlying the adverse side eﬀects of the RXR ago-
nists become better understood, the potential to enhance the
beneﬁcial eﬀects and minimize (or even abolish) the nega-
tive side eﬀects of RXR ligands may be feasible. By eliminat-
ing the alterations in the thyroid hormone axis and mod-
ifying the triglyceride liabilities, the selective RXR modu-
lator approach in the example of LG101506 is promising.
More extensive studies are clearly needed, but the global epi-
demic of obesity and type 2 diabetes highlights the opportu-
nity to further explore the therapeutic potential of retinoid
X receptor modulators for the treatment of the metabolic
syndrome.
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